Study on Atezolizumab Compared to Best Supportive Care After Chemotherapy in Lung Cancer Patients [IMpower010]

Inclusion Criteria

• Must be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a confirmed diagnosis of Stage IB-IIIA non-small cell lung cancer (NSCLC) based on specific medical criteria.
• Must have had complete surgical removal of the lung cancer 4 to 12 weeks before joining the study and be fully recovered from surgery.
• Must have had specific lymph node sampling during surgery unless certain conditions are met.
• Eligible to receive a cisplatin-based chemotherapy regimen.
• Must have adequate blood cell counts and organ function.
• Women who are not postmenopausal or surgically sterile must have a negative pregnancy test before starting chemotherapy or atezolizumab.

Exclusion Criteria

• Have any illness or condition that may interfere with understanding or following the study procedures.
• Pregnant or breastfeeding women.
• Have had prior chemotherapy for early-stage cancer within the last 5 years, unless approved by the study team.
• Have had hormonal or radiation therapy for cancer within the last 5 years.
• Have received any other investigational treatment within 28 days before joining the study.
• Have hearing impairment or known allergies to the study drugs.
• Have had previous treatments with certain immune therapies.
• Have had other cancers within the last 5 years, except for certain non-threatening types.
• Have severe allergies to certain antibodies or proteins.
• Have autoimmune diseases or certain infections like HIV, hepatitis B, or C.
• Have significant heart or lung diseases.
• Have had a bone marrow or organ transplant.
• Have any other condition that may pose a risk during the study.
• Have known PD-L1 expression status from other studies.
• Have signs of infection or have taken antibiotics recently.
• Have had major surgery recently or need major surgery during the study.
• Have received a live vaccine recently or need one during the study.
• Have taken certain immune-stimulating or suppressing medications recently.